BIO-TECHNE Corp: diluted weighted-average shares
BIO-TECHNE diluted weighted-average shares: 157.0 million shares for the year ending 2026-06-30, down 1.7% on the year. 18 values since 2009 from SEC filings.
All BIO-TECHNE Corp financial histories
At a glance
BIO-TECHNE reported diluted weighted-average shares of 157.0 million shares for the year ending 2026-06-30, down 1.7% from 159.7 million shares a year earlier. From 2009 to 2026 it grew at a compound 8.7% a year, from 37.9 million shares to 157.0 million shares. Across the last five reported years it ranged from 157.0 million shares (2026-06-30) to 164.1 million shares (2022-06-30).
Computed from the values in the table below, in shares; each links to the filing it came from.
What this measure means
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
Exact concept: us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2008-07-01 to 2026-06-30. The SEC response was captured on 2026-09-19.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-07-01 | 2026-06-30 | 157,009,000 | shares | 2026-08-24 | 10-K · 0001104659-26-100322 SEC |
| 2024-07-01 | 2025-06-30 | 159,717,000 | shares | 2026-08-24 | 10-K · 0001104659-26-100322 SEC |
| 2023-07-01 | 2024-06-30 | 160,774,000 | shares | 2026-08-24 | 10-K · 0001104659-26-100322 SEC |
| 2022-07-01 | 2023-06-30 | 161,855,000 | shares | 2025-08-22 | 10-K · 0001558370-25-011716 SEC |
| 2021-07-01 | 2022-06-30 | 164,114,000 | shares | 2024-08-22 | 10-K · 0001558370-24-012430 SEC |
| 2020-07-01 | 2021-06-30 | 161,932,000 | shares | 2023-08-23 | 10-K · 0001558370-23-015226 SEC |
| 2019-07-01 | 2020-06-30 | 39,401,000 | shares | 2022-08-24 | 10-K · 0001558370-22-013935 SEC |
| 2018-07-01 | 2019-06-30 | 38,892,000 | shares | 2021-08-25 | 10-K · 0001437749-21-020980 SEC |
| 2017-07-01 | 2018-06-30 | 38,055,000 | shares | 2020-08-26 | 10-K · 0001437749-20-018754 SEC |
| 2016-07-01 | 2017-06-30 | 37,500,000 | shares | 2019-11-06 | 10-K/A · 0001437749-19-021760 SEC |
| 2015-07-01 | 2016-06-30 | 37,326,000 | shares | 2018-08-27 | 10-K · 0001437749-18-016190 SEC |
| 2014-07-01 | 2015-06-30 | 37,231,000 | shares | 2017-09-07 | 10-K · 0001437749-17-015711 SEC |
| 2013-07-01 | 2014-06-30 | 37,005,000 | shares | 2016-08-29 | 10-K · 0001437749-16-038182 SEC |
| 2012-07-01 | 2013-06-30 | 36,900,000 | shares | 2015-08-31 | 10-K · 0001437749-15-016645 SEC |
| 2011-07-01 | 2012-06-30 | 37,006,000 | shares | 2014-08-29 | 10-K · 0001193125-14-327566 SEC |
| 2010-07-01 | 2011-06-30 | 37,172,000 | shares | 2013-08-29 | 10-K · 0001193125-13-351961 SEC |
| 2009-07-01 | 2010-06-30 | 37,347,000 | shares | 2012-08-29 | 10-K · 0001193125-12-373084 SEC |
| 2008-07-01 | 2009-06-30 | 37,900,000 | shares | 2011-08-29 | 10-K · 0001193125-11-235045 SEC |
Related BIO-TECHNE Corp histories
Inspect the source
- Entity
- BIO-TECHNE Corp / CIK 0000842023
- Captured
- SEC response SHA-256
5f064cd631289049236c7ddafd76f1bc2824b0b55936587bf5e0bb2cc7a0f677
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
The MCP server is free and MIT-licensed: npx -y canli-mcp. If these records help your research, a star on GitHub helps other researchers find them.
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000842023.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))